Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 71 entries
Sorted by: Best Match Show Resources per page
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Biologics : targets & therapy

Fecher LA, Sharfman WH.
PMID: 26604681
Biologics. 2015 Nov 06;9:129-40. doi: 10.2147/BTT.S54179. eCollection 2015.

Cutaneous basal cell carcinoma (BCC) is the most common human cancer and its incidence is rising worldwide. Ultraviolet radiation exposure, including tanning bed use, as well as host factors play a role in its development. The majority of cases...

Cite
Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics. 2015;9:129-40doi: 10.2147/BTT.S54179.
Fecher, L. A., & Sharfman, W. H. (2015). Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics : targets & therapy, 9129-40. https://doi.org/10.2147/BTT.S54179
Fecher, Leslie A, and Sharfman, William H. "Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors." Biologics : targets & therapy vol. 9 (2015): 129-40. doi: https://doi.org/10.2147/BTT.S54179
Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics. 2015 Nov 06;9:129-40. doi: 10.2147/BTT.S54179. eCollection 2015. PMID: 26604681; PMCID: PMC4642804.
Copy Download .nbib Format: NLM
Chemical Asphyxiants and Noise.

Noise & health

Fechter LD, Chen GD, Rao D.
PMID: 12678928
Noise Health. 2002;4(14):49-61.

The damaging effects of noise on auditory function can be altered significantly by exposure to additional agents that may or may not by themselves be ototoxic. This chapter focuses on the ability of chemical asphyxiants present in both occupational...

Cite
Fechter LD, Chen GD, Rao D. Chemical Asphyxiants and Noise. Noise Health. 2002;4(14):49-61
Fechter, L. D., Chen, G. D., & Rao, D. (2002). Chemical Asphyxiants and Noise. Noise & health, 4(14), 49-61.
Fechter, Laurence D., et al. "Chemical Asphyxiants and Noise." Noise & health vol. 4,14 (2002): 49-61.
Fechter LD, Chen GD, Rao D. Chemical Asphyxiants and Noise. Noise Health. 2002;4(14):49-61. PMID: 12678928.
Copy Download .nbib Format: NLM
NoiseChem: An European Commission research project on the effects of exposure to noise and industrial chemicals on hearing and balance.

Noise & health

Prasher D, Morata T, Campo P, Fechter L, Johnson AC, Lund SP, Pawlas K, Starck J, Sliwinska-Kowalska M, Sulkowski W.
PMID: 12678927
Noise Health. 2002;4(14):41-48.

Exposure to multiple physical and chemical agents is common in occupational environments but workplace hazards and occupational safety criteria for combined exposures is lacking. NoiseChem is an European Commission research project examining the effects of exposure to noise and...

Cite
Prasher D, Morata T, Campo P, et al. NoiseChem: An European Commission research project on the effects of exposure to noise and industrial chemicals on hearing and balance. Noise Health. 2002;4(14):41-48
Prasher, D., Morata, T., Campo, P., Fechter, L., Johnson, A. C., Lund, S. P., Pawlas, K., Starck, J., Sliwinska-Kowalska, M., & Sulkowski, W. (2002). NoiseChem: An European Commission research project on the effects of exposure to noise and industrial chemicals on hearing and balance. Noise & health, 4(14), 41-48.
Prasher, Deepak, et al. "NoiseChem: An European Commission research project on the effects of exposure to noise and industrial chemicals on hearing and balance." Noise & health vol. 4,14 (2002): 41-48.
Prasher D, Morata T, Campo P, Fechter L, Johnson AC, Lund SP, Pawlas K, Starck J, Sliwinska-Kowalska M, Sulkowski W. NoiseChem: An European Commission research project on the effects of exposure to noise and industrial chemicals on hearing and balance. Noise Health. 2002;4(14):41-48. PMID: 12678927.
Copy Download .nbib Format: NLM
Selective vulnerability of the cochlear Basal turn to acrylonitrile and noise.

Journal of toxicology

Pouyatos B, Gearhart CA, Nelson-Miller A, Fulton S, Fechter LD.
PMID: 20130768
J Toxicol. 2009;2009:908596. doi: 10.1155/2009/908596. Epub 2009 May 06.

Exposure to acrylonitrile, a high-production industrial chemical, can promote noise-induced hearing loss (NIHL) in the rat even though this agent does not itself produce permanent hearing loss. The mechanism by which acrylonitrile promotes NIHL includes oxidative stress as antioxidant...

Cite
Pouyatos B, Gearhart CA, Nelson-Miller A, et al. Selective vulnerability of the cochlear Basal turn to acrylonitrile and noise. J Toxicol. 2009;2009:908596doi: 10.1155/2009/908596.
Pouyatos, B., Gearhart, C. A., Nelson-Miller, A., Fulton, S., & Fechter, L. D. (2009). Selective vulnerability of the cochlear Basal turn to acrylonitrile and noise. Journal of toxicology, 2009908596. https://doi.org/10.1155/2009/908596
Pouyatos, B, et al. "Selective vulnerability of the cochlear Basal turn to acrylonitrile and noise." Journal of toxicology vol. 2009 (2009): 908596. doi: https://doi.org/10.1155/2009/908596
Pouyatos B, Gearhart CA, Nelson-Miller A, Fulton S, Fechter LD. Selective vulnerability of the cochlear Basal turn to acrylonitrile and noise. J Toxicol. 2009;2009:908596. doi: 10.1155/2009/908596. Epub 2009 May 06. PMID: 20130768; PMCID: PMC2809326.
Copy Download .nbib Format: NLM
Oxidative stress: a potential basis for potentiation of noise-induced hearing loss.

Environmental toxicology and pharmacology

Fechter LD.
PMID: 21783524
Environ Toxicol Pharmacol. 2005 May;19(3):543-6. doi: 10.1016/j.etap.2004.12.017.

In the past two decades, researchers have determined that a broad range of environmental and occupational contaminants can interact with noise to enhance noise-induced hearing loss. This manuscript focuses upon the hypothesis that chemicals that promote oxidative stress might...

Cite
Fechter LD. Oxidative stress: a potential basis for potentiation of noise-induced hearing loss. Environ Toxicol Pharmacol. 2005;19(3):543-6doi: 10.1016/j.etap.2004.12.017.
Fechter, L. D. (2005). Oxidative stress: a potential basis for potentiation of noise-induced hearing loss. Environmental toxicology and pharmacology, 19(3), 543-6. https://doi.org/10.1016/j.etap.2004.12.017
Fechter, Laurence D. "Oxidative stress: a potential basis for potentiation of noise-induced hearing loss." Environmental toxicology and pharmacology vol. 19,3 (2005): 543-6. doi: https://doi.org/10.1016/j.etap.2004.12.017
Fechter LD. Oxidative stress: a potential basis for potentiation of noise-induced hearing loss. Environ Toxicol Pharmacol. 2005 May;19(3):543-6. doi: 10.1016/j.etap.2004.12.017. PMID: 21783524.
Copy Download .nbib Format: NLM
Selective laser trabeculoplasty: Does energy dosage predict response?.

Oman journal of ophthalmology

Habib L, Lin J, Berezina T, Holland B, Fechtner RD, Khouri AS.
PMID: 24082666
Oman J Ophthalmol. 2013 May;6(2):92-5. doi: 10.4103/0974-620X.116635.

BACKGROUND: Selective laser trabeculoplasty (SLT) is a widely used treatment for open angle glaucoma, producing sustained reductions of intraocular pressure (IOP). The aim of this study was to evaluate the long-term relationship between SLT energy dosage and IOP reduction.MATERIALS...

Cite
Habib L, Lin J, Berezina T, et al. Selective laser trabeculoplasty: Does energy dosage predict response?. Oman J Ophthalmol. 2013;6(2):92-5doi: 10.4103/0974-620X.116635.
Habib, L., Lin, J., Berezina, T., Holland, B., Fechtner, R. D., & Khouri, A. S. (2013). Selective laser trabeculoplasty: Does energy dosage predict response?. Oman journal of ophthalmology, 6(2), 92-5. https://doi.org/10.4103/0974-620X.116635
Habib, Larissa, et al. "Selective laser trabeculoplasty: Does energy dosage predict response?." Oman journal of ophthalmology vol. 6,2 (2013): 92-5. doi: https://doi.org/10.4103/0974-620X.116635
Habib L, Lin J, Berezina T, Holland B, Fechtner RD, Khouri AS. Selective laser trabeculoplasty: Does energy dosage predict response?. Oman J Ophthalmol. 2013 May;6(2):92-5. doi: 10.4103/0974-620X.116635. PMID: 24082666; PMCID: PMC3779422.
Copy Download .nbib Format: NLM
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

The Journal of clinical investigation

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.
PMID: 29608143
J Clin Invest. 2018 Apr 02;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 02.

No abstract available.

Cite
Lin H, Wei S, Hurt EM, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128(4):1708doi: 10.1172/JCI120803.
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., Vats, P., Chinnaiyan, A. M., Lao, C. D., Lawrence, T. S., Wicha, M., Hamanishi, J., Mandai, M., Kryczek, I., & Zou, W. (2018). Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. The Journal of clinical investigation, 128(4), 1708. https://doi.org/10.1172/JCI120803
Lin, Heng, et al. "Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression." The Journal of clinical investigation vol. 128,4 (2018): 1708. doi: https://doi.org/10.1172/JCI120803
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018 Apr 02;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 02. PMID: 29608143; PMCID: PMC5873851.
Copy Download .nbib Format: NLM
Erratum.

RNA biology

Lioliou E, Fechter P, Caldelari I, Jester BC, Dubrac S, Helfer AC, Boisset S, Vandenesch F, Romby P, Geissmann T.
PMID: 29243975
RNA Biol. 2017 Dec 02;14(12):1827. doi: 10.1080/15476286.2016.1184436.

No abstract available.

Cite
Lioliou E, Fechter P, Caldelari I, et al. Erratum. RNA Biol. 2017;14(12):1827doi: 10.1080/15476286.2016.1184436.
Lioliou, E., Fechter, P., Caldelari, I., Jester, B. C., Dubrac, S., Helfer, A. C., Boisset, S., Vandenesch, F., Romby, P., & Geissmann, T. (2017). Erratum. RNA biology, 14(12), 1827. https://doi.org/10.1080/15476286.2016.1184436
Lioliou, Efthimia, et al. "Erratum." RNA biology vol. 14,12 (2017): 1827. doi: https://doi.org/10.1080/15476286.2016.1184436
Lioliou E, Fechter P, Caldelari I, Jester BC, Dubrac S, Helfer AC, Boisset S, Vandenesch F, Romby P, Geissmann T. Erratum. RNA Biol. 2017 Dec 02;14(12):1827. doi: 10.1080/15476286.2016.1184436. PMID: 29243975; PMCID: PMC5731809.
Copy Download .nbib Format: NLM
New Technique of Exposed Glaucoma Drainage Tube Repair: Report of a Case.

Journal of current glaucoma practice

Berezina TL, Fechtner RD, Cohen A, Kim EE, Chu DS.
PMID: 26997836
J Curr Glaucoma Pract. 2015 May-Aug;9(2):62-4. doi: 10.5005/jp-journals-10008-1185. Epub 2015 Sep 25.

We present the case of successful repair of an exposed glaucoma drainage tube by cornea graft fixation with tissue adhesive, and without subsequent coverage by adjacent conjunctiva or donor tissues. Patient with history of keratoglobus with thin cornea and...

Cite
Berezina TL, Fechtner RD, Cohen A, et al. New Technique of Exposed Glaucoma Drainage Tube Repair: Report of a Case. J Curr Glaucoma Pract. 2015;9(2):62-4doi: 10.5005/jp-journals-10008-1185.
Berezina, T. L., Fechtner, R. D., Cohen, A., Kim, E. E., & Chu, D. S. (2015). New Technique of Exposed Glaucoma Drainage Tube Repair: Report of a Case. Journal of current glaucoma practice, 9(2), 62-4. https://doi.org/10.5005/jp-journals-10008-1185
Berezina, Tamara L, et al. "New Technique of Exposed Glaucoma Drainage Tube Repair: Report of a Case." Journal of current glaucoma practice vol. 9,2 (2015): 62-4. doi: https://doi.org/10.5005/jp-journals-10008-1185
Berezina TL, Fechtner RD, Cohen A, Kim EE, Chu DS. New Technique of Exposed Glaucoma Drainage Tube Repair: Report of a Case. J Curr Glaucoma Pract. 2015 May-Aug;9(2):62-4. doi: 10.5005/jp-journals-10008-1185. Epub 2015 Sep 25. PMID: 26997836; PMCID: PMC4750028.
Copy Download .nbib Format: NLM
Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation.

EJNMMI physics

Schiller F, Fechter T, Zamboglou C, Chirindel A, Salman N, Jilg CA, Drendel V, Werner M, Meyer PT, Grosu AL, Mix M.
PMID: 28815472
EJNMMI Phys. 2017 Aug 17;4(1):21. doi: 10.1186/s40658-017-0188-1.

BACKGROUND: Implementation of PET/CT in diagnosis of primary prostate cancer (PCa) requires a profound knowledge about the tracer, preferably from a quantitative evaluation. Direct visual comparison of PET/CT slices to whole prostate sections is hampered by considerable uncertainties from...

Cite
Schiller F, Fechter T, Zamboglou C, et al. Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. EJNMMI Phys. 2017;4(1):21doi: 10.1186/s40658-017-0188-1.
Schiller, F., Fechter, T., Zamboglou, C., Chirindel, A., Salman, N., Jilg, C. A., Drendel, V., Werner, M., Meyer, P. T., Grosu, A. L., & Mix, M. (2017). Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. EJNMMI physics, 4(1), 21. https://doi.org/10.1186/s40658-017-0188-1
Schiller, F, et al. "Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation." EJNMMI physics vol. 4,1 (2017): 21. doi: https://doi.org/10.1186/s40658-017-0188-1
Schiller F, Fechter T, Zamboglou C, Chirindel A, Salman N, Jilg CA, Drendel V, Werner M, Meyer PT, Grosu AL, Mix M. Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. EJNMMI Phys. 2017 Aug 17;4(1):21. doi: 10.1186/s40658-017-0188-1. PMID: 28815472; PMCID: PMC5559412.
Copy Download .nbib Format: NLM
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K.
PMID: 34724392
J Clin Oncol. 2021 Nov 01;JCO2101440. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01.

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.METHODS: A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology,...

Cite
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;JCO2101440doi: 10.1200/JCO.21.01440.
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T., Porter, L. D., Reichner, C. A., Seigel, C., Song, J. M., Spira, A., Suarez-Almazor, M., Swami, U., Thompson, J. A., Vikas, P., Wang, Y., Weber, J. S., Funchain, P., & Bollin, K. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2101440. https://doi.org/10.1200/JCO.21.01440
Schneider, Bryan J, et al. "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2101440. doi: https://doi.org/10.1200/JCO.21.01440
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Nov 01;JCO2101440. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01. PMID: 34724392.
Copy Download .nbib Format: NLM
Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.

Cell reports. Medicine

Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, Rowley J, Gotlib J, Zehnder J, Krishnan A.
PMID: 34755136
Cell Rep Med. 2021 Oct 19;2(10):100425. doi: 10.1016/j.xcrm.2021.100425. eCollection 2021 Oct 19.

Predicting disease progression remains a particularly challenging endeavor in chronic degenerative disorders and cancer, thus limiting early detection, risk stratification, and preventive interventions. Here, profiling the three chronic subtypes of myeloproliferative neoplasms (MPNs), we identify the blood platelet transcriptome...

Cite
Shen Z, Du W, Perkins C, et al. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Rep Med. 2021;2(10):100425doi: 10.1016/j.xcrm.2021.100425.
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., Rowley, J., Gotlib, J., Zehnder, J., & Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell reports. Medicine, 2(10), 100425. https://doi.org/10.1016/j.xcrm.2021.100425
Shen, Zhu, et al. "Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms." Cell reports. Medicine vol. 2,10 (2021): 100425. doi: https://doi.org/10.1016/j.xcrm.2021.100425
Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, Rowley J, Gotlib J, Zehnder J, Krishnan A. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Rep Med. 2021 Oct 19;2(10):100425. doi: 10.1016/j.xcrm.2021.100425. eCollection 2021 Oct 19. PMID: 34755136; PMCID: PMC8561315.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 71 entries